Cuaya UCA, Martínez DA, Mejía ÁME, Carrasco DD, Suárez LTJ, Estrada GA, Galíndez HG, Carrillo RG

Language: Spanish
References: 23
Page: 151-156
PDF size: 308.83 Kb.

ABSTRACT

Human papilloma virus (HPV) is an infection disease that occurs only in humans, HPV has the capacity to infect epithelial tissues and mucous membranes. Respiratory papillomatosis could be a subclinical or clinical infectious disease. The subtypes HPV6 and HPV11 are capable to produce a recurrent respiratory papillomatosis (RRP) and are associated to exofitic lesions in the airway with aggressive behavior and risk to malign transformation. RRP has many difficulties in treatment with tendency to recurrences and widespread thought the airway, although frequently affect the larynx the trachea and lungs are also affected. The RRP is an entity related to exposition oro-respiratory that occurs at birth when contact via vaginal occurs, in RRP the firsts symptoms are manifested in the childhood (between 6 months to 10 years old) but the onset also could be in adulthood. In that situation the RRP is considered a sexual disease secondary to orogenital contact. The respiratory papillomatosis has two well known forms: one is the juvenile form or aggressive, and the other one is the adult form or less aggressive, although the aggressive form could happens in adults.

REFERENCES

1. Derkay CS. Recurrent respiratory papillomatosis. Laryngoscope 2001; 111: 57-69.

2. Derkay CS. Task force on recurrent respiratory papillomas. Arch Otolaryngol Head Neck Surg 1995; 121: 1386-1391.

3. Kashima H, Shah F, Lyles A, et al. Factors in juvenile-onset and adult onset recurrent respiratory papillomas. Laringoscope 1992; 102: 9-13.

4. Shah KV, Stern WF, Shaf PK, Bishai D, Kashima H. Risk factors for juvenile-onset recurrent respiratory papillomatosis.

5. Armstrong LR, Derkay CS, Reeves WC. Initial results from the National Registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 1999; 125: 743-748.

6. Rimell FL, Shoemaker DL, Pou AM, Jordan JA, Post CJ, Ehrlich GD. Pediatric respiratory papillomatosis: prognostic role of viral subtyping and cofactors. Laryngoscope 1997; 107: 915-918.

7. Rihkaren H, Aaltonen LM, Syranen SM. Human papilloma virus in laryngeal papillomas and in adjacent normal epithelium. Clin Otolaryngol 1993; 18: 470-474.

8. Bennett RS, Powell KR. Human papillomavirus: association between laryngeal papillomas and genital warts. Pediatr Infect Dis J 1987; 6: 229-232.

9. Von Krogh G, Lacey CJ, Gross G, et al. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 2000; 76: 162.

10. Sonnex C. Human papillomavirus infection with particular reference to genital disease. J Clin Pathol 1998; 51: 643.

11. Bonnez W, Reichman RC. Papillomaviruses. In: Principles and practice of infectious diseases. 5th ed. Mandell GL, Bennett JE, Dolin R (Eds). Churchill Livingston, Philadelphia 2000: 1630.

12. Kosko JR, Derkay CS. Role of cesarean section in prevention of recurrent respiratory papillomatosis—is there one? Int J Pediatr Otorhinolaryngol 1996; 35: 31.

13. Shikowitz MJ, Abramson AL, Freeman K, et al. Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope 1998; 108: 962.

14. Dancey DR, Chamberlain DW, Krajden M, et al. Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir: case report and review of the literature. Chest 2000; 118: 1210.

15. Bernard HU. Established and potential strategies against papillomavirus infections. J Antimicrobial Chemotherapy 2004; 53: 137-139.

16. Chhetri DK, Shapiro NL. A scheduled protocol for the treatment of juvenile recurrent respiratory papillomatosis with intralesional cidofovir. Arch Otolaryngol Head Neck Surg 2003; 129: 1081-1085.

17. Naiman A, Ceruse P. Intralesional cidofovir and surgical excision for laryngeal papillomatosis. Laryngoscope 2003; 113: 2174-2181.

18. Van Valckenborgh. Systemic cidofovir in papillomatosis. Clin Infect Dis 2001; 32(3): E62-4.

19. Armbruster C. Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon alpha-2b. Eur Respire J 2001; 17(4): 830-1.

20. Dedo HH. CO(2) laser treatment in 244 patients with respiratory papillomas. Laryngoscope 2001; 119(9): 1639-44.

21. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157: 218.

22. Sedlacek TV. Advances in the diagnosis and treatment of human papillomavirus infections. Clin Obstet Gynecol 1999; 42: 206.

23. Auborn KJ, Carter TH. Treatment of human papillomavirus gynecologic infections. Clin Lab Med 2000; 20: 407.